Adult leukemia patients get Kid-Style chemo combo in new trial
NCT ID NCT01920737
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing whether a combination of chemotherapy drugs typically used in children can be safe and effective for adults aged 18 to 60 with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). The study aims to see if this 'pediatric-inspired' regimen helps achieve deep remission with fewer side effects. Thirty-nine participants are receiving a multi-drug regimen over several phases, with close monitoring for response and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
combination chemotherapy (daunorubicin, vincristine, prednisone, PEG-asparaginase, methotrexate, 6-mercaptopurine, cyclophosphamide, cytarabine, leucovorin, dexamethasone)
What this could lead to
If successful, this could offer a more effective and safer chemotherapy regimen for adults with Ph-negative ALL, potentially improving remission rates.
What could go wrong
This is a small, early-phase (phase 2) study with only 39 participants. The regimen may not work as well in adults as in children, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center
Durham, North Carolina, 27701, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Weill Cornell Medical Center
New York, New York, United States